Importantly, the KPCA model was previously shown to be an immunologically cold tumor (low T‐cell infiltration, higher proportions of TRegs, and large fractions of suppressive myeloid cells) that required an aggressive treatment strategy of the CHK1 inhibitor Prexasertib alongside CTLA4 and PD‐L1 inhibition to reach long‐term cures. Here, CTLA4 is linked to neoplasm.